# Making Better CAR-T Cells to Fight Lymphoma

> This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects.

- **Patent:** US 12630603
- **Original title:** Chimeric antigen receptor T cell therapy
- **Owner:** Kite Pharma
- **Granted:** 2026
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, gene_editing, oncology, immunology

## What it does

The patent claims a method for making an anti-CD19 Chimeric Antigen Receptor (CAR)-T cell immunotherapy product that works better and has fewer severe side effects for Non-Hodgkin's Lymphoma (NHL) patients. It involves taking a patient's T cells and, during the manufacturing process, specifically increasing or maximizing the percentage of "naïve" CD4+ and CD8+ T cells, identified by the CD45RA+ CCR7+ markers (Claim 1). This optimized product must contain at least 20x10^6 of these specific naïve T cells, adjusted for the patient's tumor size (Claim 1). For example, a patient with relapsed/refractory large B-cell lymphoma (Claim 3) would receive a CAR-T infusion engineered with a higher proportion of these specific T cells, aiming for a more lasting response and less severe cytokine release syndrome or neurological issues (Claim 1).

## What it does NOT cover

- Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (Claim 1).
- Does not cover CAR-T cell manufacturing methods that do not ensure at least 20x10^6 of these specific naïve T cells in the final product (Claim 1).
- Does not cover CAR-T cell therapies targeting antigens other than CD19 (Claim 1).
- Does not cover CAR-T cell therapies for cancers other than Non-Hodgkin's Lymphoma, advanced-stage indolent NHL, large B-cell lymphoma, or Mantle Cell Lymphoma (Claim 3).
- Does not cover methods of simply administering CAR-T cells without a specific manufacturing step to enrich for naïve T cells.

## The clever bit

The clever bit is recognizing that not all T cells are equally effective in CAR-T therapy, and that enriching for a specific "naïve" T cell phenotype (CD45RA+ CCR7+) during manufacturing can lead to both better, more lasting cancer responses and fewer severe side effects like cytokine release syndrome.

## Real-world examples

1. Yescarta (axicabtagene ciloleucel)
2. Tecartus (brexucabtagene autoleucel)
3. Other anti-CD19 CAR-T cell therapies
4. Personalized cancer immunotherapies

## Why it matters

Chimeric Antigen Receptor (CAR)-T cell therapy is a powerful, personalized treatment for certain blood cancers, but it can have severe side effects and not all patients respond durably. This patent addresses these challenges by proposing a manufacturing method to create a more effective and safer CAR-T product. By focusing on specific T cell types, it aims to improve patient outcomes, making this advanced therapy more widely applicable and tolerable.

## Frequently asked questions

### What does Making Better CAR-T Cells to Fight Lymphoma cover?

This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects.

### Who owns patent US 12630603?

Kite Pharma owns this patent, granted in 2026.

### When does this patent expire?

This patent is expected to expire on February 20, 2041, when the invention enters the public domain.

### What problem does this patent solve?

Chimeric Antigen Receptor (CAR)-T cell therapy is a powerful, personalized treatment for certain blood cancers, but it can have severe side effects and not all patients respond durably. This patent addresses these challenges by proposing a manufacturing method to create a more effective and safer CAR-T product. By focusing on specific T cell types, it aims to improve patient outcomes, making this advanced therapy more widely applicable and tolerable.

### What does this patent NOT cover?

Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (Claim 1).

**Full plain-English explainer:** https://patentbrief.org/patent/us/12630603/chimeric-antigen-receptor-t-cell-therapy-12630603

**Original patent:** https://patents.google.com/patent/US12630603

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [Treating a Specific Lymphoma with Modified T Cells](https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy) — This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient.
- [How Genetically Modified T-Cells Attack Cancer](https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer) — This patent describes how human T cells are genetically engineered to express a special receptor (CAR) that specifically targets and kills cancer cells, particularly those with the CD19 marker, offering a new way to treat cancer.
- [How Genetically Modified T-Cells Fight CD19 Cancers](https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer) — This patent describes how to create and use genetically modified human T cells that target and kill cancer cells expressing the CD19 protein, offering a new way to treat blood cancers.
- [Gene Editing T-Cells to Fight CD7 Blood Cancers](https://patentbrief.org/patent/us/12564648/gene-editing-of-car-t-cells-for-the-treatment-of-t-cell-malignancies-with-chimer) — This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient.
- [Predicting and Treating Dangerous Side Effects in CAR T-Cell Therapy](https://patentbrief.org/patent/us/12163952/determining-toxicity-risk-in-car-t-cell-therapy) — This patent describes methods to identify patients at high risk for severe side effects, like cytokine release syndrome or neurotoxicity, during CAR T-cell cancer therapy and how to treat them proactively.
